<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1170" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1170/" /><meta name="ncbi_pagename" content="Juvenile Hereditary Hemochromatosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Juvenile Hereditary Hemochromatosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Juvenile Hereditary Hemochromatosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2011/08/11" /><meta name="citation_author" content="Y Paul Goldberg" /><meta name="citation_pmid" content="20301349" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1170/" /><meta name="citation_keywords" content="Hemochromatosis, Type 2" /><meta name="citation_keywords" content="Hemochromatosis, Type 2" /><meta name="citation_keywords" content="Hemojuvelin" /><meta name="citation_keywords" content="Hepcidin" /><meta name="citation_keywords" content="HAMP" /><meta name="citation_keywords" content="HJV" /><meta name="citation_keywords" content="Juvenile Hereditary Hemochromatosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Juvenile Hereditary Hemochromatosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Y Paul Goldberg" /><meta name="DC.Date" content="2011/08/11" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1170/" /><meta name="description" content="Juvenile hemochromatosis is characterized by onset of severe iron overload occurring typically in the first to third decades of life. Males and females are equally affected. Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, arthropathy, and liver fibrosis or cirrhosis. Hepatocellular cancer has not been reported. The main cause of death is cardiac disease. If juvenile hemochromatosis is detected early enough and if blood is removed regularly through the process of phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced." /><meta name="og:title" content="Juvenile Hereditary Hemochromatosis" /><meta name="og:type" content="book" /><meta name="og:description" content="Juvenile hemochromatosis is characterized by onset of severe iron overload occurring typically in the first to third decades of life. Males and females are equally affected. Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, arthropathy, and liver fibrosis or cirrhosis. Hepatocellular cancer has not been reported. The main cause of death is cardiac disease. If juvenile hemochromatosis is detected early enough and if blood is removed regularly through the process of phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1170/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/jh/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1170/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D65BEE0403EC1000000000979036A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1170_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1170_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ebj/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/jps/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1170_"><span class="title" itemprop="name">Juvenile Hereditary Hemochromatosis</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Hemochromatosis, Type 2</div><p class="contrib-group"><span itemprop="author">Y Paul Goldberg</span>, MB ChB, PhD, FRCPC.</p><a data-jig="ncbitoggler" href="#__NBK1170_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1170_ai__"><div class="contrib half_rhythm"><span itemprop="author">Y Paul Goldberg</span>, MB ChB, PhD, FRCPC<div class="affiliation small">Vice President, Clinical Development<br />Xenon Pharmaceuticals Inc<br />Burnaby, British Columbia, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.amrahp-nonex@grebdlogp" class="oemail">moc.amrahp-nonex@grebdlogp</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 17, 2005</span>; Last Update: <span itemprop="dateModified">August 11, 2011</span>.</p><p><em>Estimated reading time: 27 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="jh.Summary" itemprop="description"><h2 id="_jh_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Juvenile hemochromatosis is characterized by onset of severe iron overload occurring typically in the first to third decades of life. Males and females are equally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, arthropathy, and liver fibrosis or cirrhosis. Hepatocellular cancer has not been reported. The main cause of death is cardiac disease. If juvenile hemochromatosis is detected early enough and if blood is removed regularly through the process of phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Serum ferritin concentration ranges from 1,000 to 7,000 &#x000b5;g/L. Transferrin-iron saturation is typically very high, often reaching 100%. MRI is used as a noninvasive method of quantifying hepatic iron overload. A hepatic iron index of higher than 1.9 on liver biopsy suggests iron overload. The two genes in which pathogenic variants are known to cause juvenile hemochromatosis are <i>HJV</i> (<i>HFE2</i>) (<a class="def" href="/books/n/gene/glossary/def-item/locus-name/">locus name</a> HFE2A) encoding hemojuvelin, accounting for more than 90% of cases, and <i>HAMP</i> (<i>HEPC</i>) (locus name HFE2B) encoding hepcidin, accounting for fewer than 10% of cases.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Phlebotomy for treatment of iron overload is the same as for classic HFE-associated hemochromatosis, i.e., phlebotomy of one unit of blood (~200 mg of iron) one to two times per week for up to two to three years to reduce iron stores to desired levels (serum ferritin concentration below 50 ng/mL and normal transferrin-iron saturation), followed by phlebotomies to maintain normal serum iron studies. Conventional treatment of secondary complications, including hypogonadotropic hypogonadism, arthropathy, cardiac failure, liver disease, diabetes mellitus.</p><p><i>Prevention of primary manifestations:</i> Regular phlebotomies until excess iron stores are depleted.</p><p><i>Prevention of secondary complications:</i> Hormone replacement therapy (HRT) to prevent osteoporosis.</p><p><i>Surveillance:</i> Monitor those at risk with annual measurement of serum ferritin concentration and transferrin-iron saturation starting in early childhood. For those with hepatic cirrhosis, monitor for hepatocellular cancer with biannual abdominal ultrasound examination and serum alpha-fetoprotein concentration.</p><p><i>Agents/circumstances to avoid:</i> Alcohol consumption; ingestion of iron-containing preparations and supplemental vitamin C; handling or eating uncooked shellfish or marine fish because of risk of fatal septicemia from the marine bacterium <i>V vulnificus</i>.</p><p><i>Evaluation of relatives at risk:</i> Biochemical testing (i.e., serum ferritin concentration and transferrin-iron saturation) or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in relatives at risk before evidence of organ damage from iron overload; monitor sibs with annual measurement of serum ferritin concentration and transferrin-iron saturation starting in early childhood.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Juvenile hemochromatosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an unaffected <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing are possible if both pathogenic variants have been identified in the family; however, requests for prenatal testing for conditions which (like juvenile hereditary hemochromatosis) do not affect intellect and have effective treatment available are not common.</p></div></div><div id="jh.Diagnosis"><h2 id="_jh_Diagnosis_">Diagnosis</h2><div id="jh.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>Juvenile hemochromatosis (JHH) should be suspected in any child, adolescent, or young adult with findings of iron overload; such findings include the following:</p><ul><li class="half_rhythm"><div>Hypogonadotropic hypogonadism</div></li><li class="half_rhythm"><div>Hepatomegaly</div></li><li class="half_rhythm"><div>Hepatic cirrhosis</div></li><li class="half_rhythm"><div>Hepatocellular carcinoma</div></li><li class="half_rhythm"><div>Diabetes mellitus</div></li><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Arrhythmias</div></li><li class="half_rhythm"><div>Arthritis</div></li><li class="half_rhythm"><div>Progressive increase in skin pigmentation</div></li></ul><p>Many of these features are evident before age 30 years.</p><p>Presenting symptoms in the first or second decade may be less specific; they include lack of appetite, fatigue, amenorrhea, or arthralgia.</p></div><div id="jh.Testing"><h3>Testing</h3><p><b>Biochemical testing.</b> Data are limited as documented cases of juvenile hemochromatosis are rare; however, the following two biochemical measurements should be performed:</p><ul><li class="half_rhythm"><div><b>Serum ferritin concentration,</b> which ranges from 1000 to 7000 &#x000b5;g/L in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (normal: 20-260 &#x000b5;g/L for male children/adolescents; 5-140 &#x000b5;g/L for female children/adolescents, 25-300 &#x000b5;g/L for adult males, and 25-200 &#x000b5;g/L for adult females)</div></li><li class="half_rhythm"><div><b>Transferrin-iron saturation,</b> which is typically very high, often reaching 100% (normal: 15%-50% in children/adolescents; ~ 33% in adults)</div></li></ul><p><b>Imaging</b></p><ul><li class="half_rhythm"><div><b>Magnetic resonance imaging (MRI)</b> has become a valuable noninvasive technique to quantify hepatic iron overload [<a class="bk_pop" href="#jh.REF.gandon.2004.357">Gandon et al 2004</a>].</div></li><li class="half_rhythm"><div><b>Superconducting quantum interference device (SQUID)</b> is a noninvasive method for quantifying liver iron biomagnetometry [<a class="bk_pop" href="#jh.REF.fung.2004.5">Fung et al 2004</a>].</div></li></ul><p><b>Liver biopsy.</b> A hepatic iron index of higher than 1.9 suggests iron overload in <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a>. Similarly, because iron overload is more severe in juvenile hemochromatosis, an index of higher than 1.9 also applies for juvenile hemochromatosis (normal: &#x0003c;1.0) [<a class="bk_pop" href="#jh.REF.pietrangelo.2004.2383">Pietrangelo 2004</a>].</p><div id="jh.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>Genes.</b> Mutation of two genes is currently known to cause juvenile hemochromatosis:</p><ul><li class="half_rhythm"><div><i>HJV</i> (<i>HFE2</i>) (<a class="def" href="/books/n/gene/glossary/def-item/locus-name/">locus name</a> HJV [HFE2A]) encoding hemojuvelin, accounts for more than 90% of cases reported to date.</div></li><li class="half_rhythm"><div><i>HAMP (HEPC)</i> (<a class="def" href="/books/n/gene/glossary/def-item/locus-name/">locus name</a> HFE2B) encoding hepcidin, accounts for fewer than 10% of cases reported to date.</div></li></ul><p><b>Clinical testing</b></p><p><b><i>HJV</i></b></p><ul><li class="half_rhythm"><div><b>Sequence analysis or scanning for pathogenic variants</b> detects pathogenic variants in more than 98% of individuals with <i>HJV</i>-related juvenile hemochromatosis. Neither <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> nor scanning for pathogenic variants detects <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions.</div></li><li class="half_rhythm"><div><b>Targeted analysis for</b>
<b>pathogenic variants.</b> To date, the most frequently reported <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>HJV</i> is p.Gly320Val; it accounted for two thirds of pathogenic variants identified in the original <i>HJV</i> positional cloning report [<a class="bk_pop" href="#jh.REF.papanikolaou.2004.77">Papanikolaou et al 2004</a>]. The p.Gly320Val pathogenic variant was identified in all French-Canadian individuals with juvenile hemochromatosis phenotypes from the Saguenay-Lac-Saint-Jean region [<a class="bk_pop" href="#jh.REF.lanzara.2004.4317">Lanzara et al 2004</a>].</div></li></ul><p><b><i>HAMP</i></b></p><ul><li class="half_rhythm"><div><b>Sequence analysis or scanning</b>
<b>for</b>
<b>pathogenic variants</b> detects pathogenic variants in more than 98% of individuals with <i>HAMP</i>-related juvenile hemochromatosis. Neither <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> nor scanning for pathogenic variants detects <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions.</div></li></ul><div id="jh.T.molecular_genetic_testing_used_in_j" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Juvenile Hereditary Hemochromatosis (JHH)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1170/table/jh.T.molecular_genetic_testing_used_in_j/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__jh.T.molecular_genetic_testing_used_in_j_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of JHH Caused by Mutation of This Gene</th><th id="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HJV</i></td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants</td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly320Val</td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 4</td></tr><tr><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%</td></tr><tr><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HAMP</i></td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;10%</td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_jh.T.molecular_genetic_testing_used_in_j_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="jh.TF.1.1"><p class="no_margin">See <a href="/books/NBK1170/#jh.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="jh.TF.1.2"><p class="no_margin">See <a href="#jh.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="jh.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="jh.TF.1.4"><p class="no_margin">Most frequently reported <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#jh.REF.papanikolaou.2004.77">Papanikolaou et al 2004</a>]; identified in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> French-Canadian individuals from the Saguenay-Lac-Saint-Jean region [<a class="bk_pop" href="#jh.REF.lanzara.2004.4317">Lanzara et al 2004</a>]</p></div></dd><dt>5. </dt><dd><div id="jh.TF.1.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="jh.TF.1.6"><p class="no_margin">Sequence analysis and scanning of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> for pathogenic variants can have similar detection frequencies; however, detection rates for scanning may vary considerably among laboratories depending on the specific protocol used.</p></div></dd></dl></div></div></div></div></div><div id="jh.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To establish the diagnosis of juvenile hemochromatosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>,</b> the following tests are used:</p><ul><li class="half_rhythm"><div class="half_rhythm">Biochemical testing (high serum ferritin concentration; high transferrin-iron saturation)</div></li><li class="half_rhythm"><div class="half_rhythm">Molecular testing of <i>HJV</i> and <i>HAMP</i></div><ul><li class="half_rhythm"><div>Perform targeted analysis for the p.Gly320Val <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in <i>HJV</i>, if no or only one p.Gly320Val allele is identified, continue with <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> / scanning of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> for pathogenic variants; OR</div></li><li class="half_rhythm"><div>Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> / scanning of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> for pathogenic variants; if neither or only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>HJV</i> is identified, perform sequence analysis / scanning of <i>HAMP</i> for pathogenic variants.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">If <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants are not identified in either <i>HJV</i> or <i>HAMP</i>, consider testing for <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hemochromatosis</a>. However, the clinical relevance of identifying one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>HJV</i> or <i>HAMP</i> and <i>HFE</i> or two pathogenic variants in <i>HFE</i> and one in one of the other two genes is unknown. (See <a href="#jh.Differential_Diagnosis">Differential Diagnosis</a>.)</div></li><li class="half_rhythm"><div class="half_rhythm">Hepatic imaging</div></li><li class="half_rhythm"><div class="half_rhythm">Possible liver biopsy</div><div class="half_rhythm">Note: Liver biopsy is usually used for prognostication (see <a href="#jh.Evaluations_Following_Initial_Diagnos">Management</a>); however, it may be used infrequently for diagnosis. Guidelines for biopsy are not defined for JHH.</div></li></ul><p><b>Carrier testing for at-risk relatives</b> requires prior identification of the pathogenic variants in the family.</p><p>Note: Carriers are heterozygotes for an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder and are not at risk of developing the disorder.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p></div></div><div id="jh.Clinical_Characteristics"><h2 id="_jh_Clinical_Characteristics_">Clinical Characteristics</h2><div id="jh.Clinical_Description"><h3>Clinical Description</h3><p>Juvenile hemochromatosis (JHH) is characterized by early onset of severe iron overload. Juvenile hemochromatosis typically presents in the first to third decade of life; however, the adult presentation of three individuals with <i>HJV</i> pathogenic variants [<a class="bk_pop" href="#jh.REF.koyama.2005.740">Koyama et al 2005</a>] highlights the wide spectrum of disease phenotypes related to <i>HJV</i> pathogenic variants: from classic JHH at one extreme to late onset adult form at the other extreme.</p><p>Males and females are equally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>In clinical practice, individuals with juvenile hemochromatosis are rarely diagnosed before significant iron overload occurs.</p><p>Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, arthropathy, and liver fibrosis or cirrhosis. Osteopenia and osteoporosis are common complications in individuals with prolonged hypogonadism [<a class="bk_pop" href="#jh.REF.vaiopoulos.2003.227">Vaiopoulos et al 2003</a>]. The clinical course is severe, with the main cause of death being cardiac-related disease [<a class="bk_pop" href="#jh.REF.de_gobbi.2002.973">De Gobbi et al 2002</a>]. The prevalence of cardiac disease is strikingly high and in some instances is the presenting finding [<a class="bk_pop" href="#jh.REF.filali.2004.120">Filali et al 2004</a>].</p><p>Although individuals with juvenile hemochromatosis may develop adrenocortical insufficiency or hypothyroidism, these complications are rare [<a class="bk_pop" href="#jh.REF.varkonyi.2000.252">Varkonyi et al 2000</a>]. While diabetes is common in individuals with <i>HFE</i>-related hemochromatosis, the extent of glucose impairment in people with JHH has not been well defined. However, in one study of 26 patients from 20 families with JHH, reduced glucose tolerance was identified in 58% [<a class="bk_pop" href="#jh.REF.de_gobbi.2002.973">De Gobbi et al 2002</a>].</p><p>Despite the more severe iron overload seen in juvenile hemochromatosis (as compared to <i>HFE</i>-associated hereditary hemochromatosis), hepatocellular cancer has not been reported in juvenile hemochromatosis [<a class="bk_pop" href="#jh.REF.camaschella.2002.242">Camaschella et al 2002</a>]; a possible explanation is that untreated individuals with juvenile hemochromatosis die prematurely as a result of cardiac complications [<a class="bk_pop" href="#jh.REF.camaschella.1998.227">Camaschella 1998</a>].</p><p>If juvenile hemochromatosis is detected early enough and blood is removed regularly through the process of phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced.</p></div><div id="jh.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been reported with <i>HJV</i>-related juvenile hemochromatosis or <i>HAMP</i>-related juvenile hemochromatosis; the clinical and biochemical phenotypes reported for all pathogenic variants identified so far appear similar.</p><p><a class="bk_pop" href="#jh.REF.koyama.2005.740">Koyama et al [2005]</a> reported three Japanese individuals (two from the same family) presenting around age 50 years with typical clinical signs of JHH and hepatic histologic damage compatible with hemochromatosis. All three were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for an <i>HJV</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><ul><li class="half_rhythm"><div>One was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the novel pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant 745G&#x0003e;C (p.Asp249His), suggesting that the variant, which results in a relatively mild late-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, may not be highly detrimental to hemojuvelin functioning.</div></li><li class="half_rhythm"><div>The two from the same family were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for another novel <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, 934C&#x0003e;T (p.Gln312Ter), which induced a premature stop codon, suggesting that unidentified factor(s) in this family may modify the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, as other truncating pathogenic variants typically have a more severe clinical presentation.</div></li></ul><p>In a given individual, the degree of iron loading and the resultant clinical severity ultimately depends on the combination of genetic and environmental load. For example:</p><ul><li class="half_rhythm"><div><a class="bk_pop" href="#jh.REF.brakensiek.2009.493">Brakensiek et al [2009]</a> reported a male with severe JHH who died at age 21 years as a result of severe cardiomyopathy resulting from excessive iron loading. He was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the common <i>HJV</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Gly320Val<i>,</i> <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for the <i>HFE</i> pathogenic variants p.His63Asp and p.Ser65Cys<i>,</i> and homozygous for the <i>HFE</i> pathogenic variant IVS2+4T&#x0003e;C, leading the authors to hypothesize that the <i>HFE</i> pathogenic variants may have exacerbated the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in this patient.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#jh.REF.gehrke.2005.425">Gehrke et al [2005]</a> observed that an individual who was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>HJV</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Gly320Val and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>HFE</i> pathogenic variant p.Cys282Tyr had a more severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li></ul></div><div id="jh.Nomenclature"><h3>Nomenclature</h3><p>Despite use of the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> names HFE2A and HFE2B for the two juvenile hemochromatosis genes, juvenile hemochromatosis is not associated with pathogenic variants in <i>HFE</i> &#x02013; mutation of which causes <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a>, an adult-onset disorder of iron storage.</p><p>To avoid confusion, all researchers/physicians now prefer to use the <a class="def" href="/books/n/gene/glossary/def-item/locus-name/">locus name</a> HJV (rather than HFE2A) and the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> symbol <i>HJV</i> for the common juvenile hemochromatosis gene that encodes hemojuvelin.</p></div><div id="jh.Prevalence"><h3>Prevalence</h3><p>Juvenile hemochromatosis is rare.</p><p>Affected individuals have been reported worldwide.</p><p>Pathogenic variants in <i>HJV</i> represent the majority of worldwide cases of juvenile hemochromatosis. To date, <i>HJV</i>-related juvenile hemochromatosis has been reported in individuals of Northern European (including Canadian, American, and Australian) ethnicities; Italian, Greek, Dutch, Albanian, Hungarian, Romanian, Japanese, and Chinese descent; and in the French-Canadian region of Saguenay-Lac-Saint-Jean. No particular ethnic background appears to have a higher frequency; however, a clustering of <i>HJV</i> pathogenic variants occurs in Italy and Greece.</p><p>A much smaller number of individuals of Italian, Greek, Arab, and Portuguese descent with <i>HAMP</i>-related juvenile hemochromatosis have been reported.</p></div></div><div id="jh.Genetically_Related_Allelic_Disorders"><h2 id="_jh_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p>To date, no other phenotypes are known to be caused by mutation of <i>HJV</i> or <i>HAMP</i>.</p></div><div id="jh.Differential_Diagnosis"><h2 id="_jh_Differential_Diagnosis_">Differential Diagnosis</h2><p>Iron overload phenotypes can be primary or secondary.</p><p><b>Primary iron overload phenotypes</b> include the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a> (adult-onset classic hemochromatosis, type 1 hemochromatosis, HFE1). At the milder end of the spectrum, classic hereditary hemochromatosis is known to be caused by <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants in <i>HFE</i>, with clinical features typically presenting in the 40s to 50s in contrast to juvenile hemochromatosis, which typically presents before age 30 years. <i>HFE</i>-associated hereditary hemochromatosis, considered the classic and most common form, has many features in common with juvenile hemochromatosis, including hypogonadotropic hypogonadism, cardiomyopathy, diabetes mellitus, hepatic cirrhosis, and skin hyperpigmentation; however, the clinical findings of juvenile hemochromatosis are much more severe than those seen in classic hereditary hemochromatosis because of the much higher rate of iron accumulation in the former. In particular, in juvenile hemochromatosis the clinical features of hypogonadotropic hypogonadism and cardiomyopathy are more prominent than those in classic hereditary hemochromatosis [<a class="bk_pop" href="#jh.REF.camaschella.2002.242">Camaschella et al 2002</a>]. Classic hereditary hemochromatosis is caused by increased intestinal iron absorption as a result of a defect in the HFE protein.</div><div class="half_rhythm">Controversy exists as to the exact <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of hereditary hemochromatosis, although it is widely accepted that classic hereditary hemochromatosis, in contrast to juvenile hemochromatosis, is a low-penetrant disorder. In both juvenile hemochromatosis and classic hereditary hemochromatosis, macrophages are iron depleted despite total body iron excess.</div><div class="half_rhythm">An intermediate iron overload <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has been described in individuals with <a class="def" href="/books/n/gene/glossary/def-item/digenic/">digenic</a> inheritance of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> mutations in <i>HAMP</i> and <i>HFE</i> or heterozygous mutations in <i>HJV</i> and <i>HFE</i>. The reports suggest that an explanation for the low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> rate in classic hereditary hemochromatosis is the need for genetic modifiers, such as mutations in <i>HJV</i> and <i>HAMP</i>, in addition to mutations in <i>HFE</i> to produce the classic hereditary hemochromatosis disease phenotype. However, because digenic inheritance accounts for a small proportion of individuals with classic <i>HFE</i>-associated hereditary hemochromatosis reported to date, other mechanisms are likely to modify penetrance. Further investigation of the importance of <i>HJV</i>, <i>HAMP</i>, <i>HFE</i>, and other iron metabolism-related alleles in the clinical expression of iron overload is warranted [<a class="bk_pop" href="#jh.REF.lee.2002.471">Lee et al 2002</a>, <a class="bk_pop" href="#jh.REF.merryweatherclarke.2003.2241">Merryweather-Clarke et al 2003</a>, <a class="bk_pop" href="#jh.REF.lanzara.2004.4317">Lanzara et al 2004</a>, <a class="bk_pop" href="#jh.REF.lee.2004a.4669">Lee et al 2004a</a>, <a class="bk_pop" href="#jh.REF.lee.2004b.224">Lee et al 2004b</a>, <a class="bk_pop" href="#jh.REF.le_gac.2004.674">Le Gac et al 2004</a>, <a class="bk_pop" href="#jh.REF.majore.2004.400">Majore et al 2004</a>, <a class="bk_pop" href="#jh.REF.pietrangelo.2004.2383">Pietrangelo 2004</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/tfr2/">TFR2 (transferrin receptor 2)-related hemochromatosis</a> (type 3 hemochromatosis, HFE3). The iron overload <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is variable: in some families, adult onset (similar to that seen in classic <i>HFE</i>-associated hereditary hemochromatosis) is observed; in others, the onset occurs before adulthood but later than in juvenile-onset hemochromatosis [<a class="bk_pop" href="#jh.REF.camaschella.2000.14">Camaschella et al 2000</a>, <a class="bk_pop" href="#jh.REF.le_gac.2004.674">Le Gac et al 2004</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><i>HFE</i> (p.Cys282Tyr/p.His63Asp compound heterozygosity) and transferrin receptor 2 (p.Gln317Ter homozygosity). A few individuals clinically diagnosed with juvenile hemochromatosis have not had pathogenic variants in either <i>HJV</i> or <i>HAMP</i>. In a family with typical clinical findings of JHH in adolescence, no pathogenic variants were identified in either <i>HJV</i> or <i>HAMP</i>; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were compound heterozygotes for the <i>HFE</i> pathogenic variants p.Cys282Tyr/p.His63Asp and <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>TFR2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Gln317Ter [<a class="bk_pop" href="#jh.REF.pietrangelo.2005.470">Pietrangelo et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Ferroportin (<i>SLC40A1</i>)-related iron overload (ferroportin disease; type 4 hemochromatosis, HFE4): Individuals with pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding ferroportin also have iron overload; however, unlike individuals with juvenile hemochromatosis and classic <i>HFE</i>-associated hereditary hemochromatosis, they show macrophages that are iron laden. Affected individuals have high serum ferritin concentration despite normal/low transferrin-iron saturation at early stages of the disease. Mild anemia can accompany the disease. Anemia may occur early in therapeutic phlebotomy. Ferroportin-related iron overload presents in adulthood and is transmitted in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner [<a class="bk_pop" href="#jh.REF.montosi.2001.619">Montosi et al 2001</a>, <a class="bk_pop" href="#jh.REF.njajou.2001.213">Njajou et al 2001</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">It is now apparent that different <i>SLC40A1</i> pathogenic variants can culminate in different iron overload phenotypes [<a class="bk_pop" href="#jh.REF.de_domenico.2006.92">De Domenico et al 2006</a>]. Ferroportin mutated proteins can be divided into the following two main classes:</div><ul><li class="half_rhythm"><div>Proteins that fail to localize to the cell surface and are thus unable to export iron. Affected individuals have typical ferroportin disease with low transferrin saturation and early K&#x000fc;pffer cell iron loading</div></li><li class="half_rhythm"><div>Proteins that localize to the cell surface but are not responsive to the hepcidin (i.e., the cells show hepcidin resistance). Affected individuals have high transferrin saturation and early hepatocyte iron loading similar to classic <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a> [<a class="bk_pop" href="#jh.REF.de_domenico.2006.92">De Domenico et al 2006</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Neonatal hemochromatosis. Iron overload occurs in utero. This severe, often fatal iron overload syndrome usually presents at birth. Inheritance is unknown; however, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/mitochondrial-inheritance/">mitochondrial inheritance</a> have been postulated. No genetic <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> has been identified. It has recently been suggested that the fetal liver injury that characterizes neonatal hemochromatosis is the result of maternal alloimmunity. This suggestion is supported by the observation that recurrence rates in families with neonatal hemochromatosis are far greater (&#x02265;90%) than would be predicted by Mendelian inheritance. Furthermore, in women with a history of pregnancy resulting in neonatal hemochromatosis, treatment with high-dose IVIG reduced the risk of having a severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child [<a class="bk_pop" href="#jh.REF.whitington.2005.544">Whitington &#x00026; Malladi 2005</a>, <a class="bk_pop" href="#jh.REF.whitington.2008.e1615">Whitington &#x00026; Kelly 2008</a>, <a class="bk_pop" href="#jh.REF.rand.2009.566">Rand et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Atransferrinemia. Atransferrinemia is characterized by absent transferrin and, therefore, an inability to deliver iron to the red cell precursors in the bone marrow. This lack of iron for the red cell precursors sets up a powerful erythroid drive with massive intestinal hyperabsorption of iron. Affected individuals are iron overloaded, yet have a microcytic anemia. This condition is an exceedingly rare <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder, with only a few individuals reported worldwide. Hypotransferrinemia is a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that is allelic with atransferrinemia.</div></li></ul><p><b>Secondary disorders of iron overload</b> include the following:</p><ul><li class="half_rhythm"><div>African iron overload. African iron overload occurs in individuals with a predisposition to iron overload that is exacerbated by excessive intake of dietary iron. It is particularly prevalent among Africans who drink a traditional beer brewed in non-galvanized steel drums. In the past, African iron overload was mainly attributed to dietary excess alone. However, serious iron overload does not develop in all beer drinkers, and not all individuals with iron overload consume excessive amounts of the beer, suggesting that other yet-to-be defined iron-related genes predispose to the condition. A specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Gln248His) in <i>SCL40A1</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding ferroportin 1, has been associated with tendency to iron overload in Africans and African Americans [<a class="bk_pop" href="#jh.REF.beutler.2003.305">Beutler et al 2003</a>, <a class="bk_pop" href="#jh.REF.gordeuk.2003.299">Gordeuk et al 2003</a>].</div></li><li class="half_rhythm"><div>Transfusional iron overload. Individuals receiving red blood cell transfusions or any products containing red blood cells on a regular basis develop iron overload as a result of the transfused iron.</div></li><li class="half_rhythm"><div>Nontransfusional iron overload. Nontransfusional iron overload can occur in conditions in which ongoing erythroid destruction generates an erythroid drive signaling intestinal iron hyperabsorption. For example, iron overload is a feature in <a href="/books/n/gene/b-thal/">beta-thalassemia</a> intermedia, for which most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are not transfused. Other examples include <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> dyserythropoetic anemia and <a href="/books/n/gene/sider-anemia/">sideroblastic anemia</a>.</div></li></ul><p><b>Disorders of excess ferritin without iron overload</b> include the following:</p><ul><li class="half_rhythm"><div>Hyperferritinemia cataract syndrome (HCS). Individuals with HCS do not have iron overload. They have very high serum ferritin concentration caused by a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the iron-responsive element in the 5' untranslated region of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the ferritin light chain that leads to inappropriate excessive production of ferritin. Transferrin-iron saturation is normal. Individuals with HCS have early-onset bilateral (often <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>) cataracts. Phlebotomy is contraindicated in these individuals [<a class="bk_pop" href="#jh.REF.girelli.1995.4050">Girelli et al 1995</a>, <a class="bk_pop" href="#jh.REF.aguilarmartinez.1996.1895">Aguilar-Martinez et al 1996</a>].</div></li></ul></div><div id="jh.Management"><h2 id="_jh_Management_">Management</h2><div id="jh.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with juvenile hemochromatosis, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div><b>Serum iron status.</b> Measurements of serum iron concentration, total iron binding capacity, transferrin saturation, and serum ferritin concentration</div></li><li class="half_rhythm"><div><b>Pituitary-gonadal axis.</b> Recording of signs and symptoms of hypogonadotropic hypogonadism and measurement of serum concentration of gonadotropins (i.e., FSH, LH) (pituitary gland) and testosterone (testes) or estradiol (ovaries). In several clinical situations, a dynamic evaluation of the pituitary-gonadal axis is required, consisting mainly of a GnRH (gonadotropic releasing hormone) stimulation test. Pituitary MRI may be considered in some cases.</div></li><li class="half_rhythm"><div><b>Affected joints.</b> Radiographic evaluation</div></li><li class="half_rhythm"><div><b>Bone mineral density.</b> Dual photon absorptiometry of the lumbar spine</div></li><li class="half_rhythm"><div><b>Cardiac manifestations.</b> ECG, transthoracic echocardiogram. In individuals without overt clinical manifestations of cardiac failure or arrhythmias, findings suggestive of left ventricular diastolic dysfunction (reduced left ventricular compliance) often precede evidence of ventricular dilatation and compromised ejection fraction.</div></li><li class="half_rhythm"><div><b>Liver function.</b> Liver histology to determine the extent of liver damage. Documentation of the presence or absence of cirrhosis is of prognostic significance. Current recommendations for <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated classic hereditary hemochromatosis</a> are that <i>HFE</i> p.Cys282Tyr homozygotes with serum ferritin concentration lower than 1000 ng/mL and/or normal liver function enzymes need not be biopsied. Liver biopsy should be considered for individuals with higher serum ferritin concentrations and/or raised liver function enzymes in order to establish prognosis [<a class="bk_pop" href="#jh.REF.morrison.2003.627">Morrison et al 2003</a>]. Because of the rarity of juvenile hemochromatosis, a specific protocol for individuals with juvenile hemochromatosis is not available, but adaptation of the classic <i>HFE</i>-associated hereditary hemochromatosis recommendation is a reasonable approach.</div></li><li class="half_rhythm"><div><b>Diabetes mellitus.</b> Screening for diabetes mellitus by overnight fasting plasma glucose measurement and, when indicated, by oral glucose tolerance test.</div></li></ul></div><div id="jh.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management and treatment recommendations for juvenile hemochromatosis stated here are based on the established <i>HFE</i>-associated hemochromatosis recommendations when specific juvenile hemochromatosis information may not exist.</p><p><b>Treatment of iron overload.</b> Phlebotomy is the therapy of choice in juvenile hemochromatosis and follows the same principles as the treatment of classic <i>HFE</i>-associated hemochromatosis. It is simple, safe, and effective. Affected individuals should be encouraged to follow a regimen of phlebotomy of one unit of blood once or twice weekly [Tavill 2001]. Approximately 200 mg of iron are removed per unit of blood depending on the individual's hematocrit. Because individuals with juvenile hemochromatosis are usually severely iron overloaded, a therapeutic regimen of one to two weekly phlebotomies may take up to two to three years to reduce iron stores to desired levels.</p><p>The hematocrit should be monitored prior to phlebotomy; phlebotomy should be postponed if the hematocrit drops more than 20% of its initial value [Tavill 2001]. Systematic administration of erythropoietin has been successful in maintaining the hematocrit in individuals who failed to mount an adequate bone marrow response to the phlebotomy regimen [<a class="bk_pop" href="#jh.REF.de_gobbi.2000.865">De Gobbi et al 2000</a>].</p><p>Serum ferritin concentration reflects body iron stores and is used to monitor the progress of therapy; it is expected to fall progressively, along with iron mobilization. Measuring serum ferritin concentration every 10-12 phlebotomies is reasonable; however, once serum ferritin concentration is below 100 ng/mL, it should be measured more often, ideally prior to each phlebotomy. Achievement of serum ferritin concentration below 50 ng/mL and restoration of normal transferrin-iron saturation indicates the end point of the intensive phlebotomy treatment.</p><p><b>Maintenance therapy.</b> The frequency of phlebotomies is adjusted to maintain normal serum ferritin concentration and transferrin-iron saturation. When iron removal is not urgent, phlebotomies could be spaced further apart according to the responsiveness of the bone marrow to restore adequate hematocrit. Usually four to six phlebotomies annually are sufficient. The individual should permanently continue on this schedule of phlebotomy maintenance therapy.</p><p>Iron chelators such as parenteral deferoxamine (Desferal<sup>&#x000ae;</sup>) are used to treat individuals with secondary iron overload. They are not recommended in the treatment of juvenile hemochromatosis unless the disease is complicated by concomitant anemia or severe cardiac failure. In the latter situation, administration of deferoxamine alone or in combination with deferiprone can reduce mortality by improving left ventricular ejection fraction [<a class="bk_pop" href="#jh.REF.kelly.1998.607">Kelly et al 1998</a>, <a class="bk_pop" href="#jh.REF.fabio.2007.362">Fabio et al 2007</a>].</p><p><b>Treatment of secondary complications.</b> Treatment does not essentially differ from the conventional treatment applied in other situations:</p><ul><li class="half_rhythm"><div>Hypogonadotropic hypogonadism is generally considered irreversible, despite adequate iron removal. However, reversal of hypogonadism has been observed in some young individuals who have been successfully treated with phlebotomy or iron chelation [<a class="bk_pop" href="#jh.REF.angelopoulos.2005.1744">Angelopoulos et al 2005</a>]. For the majority of individuals with hypogonadism, testosterone or hormone replacement therapy (HRT) is required to improve symptoms and prevent the development of secondary osteopenia or osteoporosis [<a class="bk_pop" href="#jh.REF.angelopoulos.2006.150">Angelopoulos et al 2006</a>].</div></li><li class="half_rhythm"><div>Transdermal preparations (i.e., patches) deliver testosterone or estradiol at a controlled rate into the systemic circulation, avoiding first-pass hepatic metabolism; therefore, this approach may be useful for individuals with juvenile hemochromatosis, eliminating the risk of potential liver complications.</div></li><li class="half_rhythm"><div>Administration of gonadotropins has restored fertility and has led to a twin pregnancy in a woman with juvenile hemochromatosis.</div></li><li class="half_rhythm"><div>Arthropathy is not modified by treatment. Individuals with juvenile hemochromatosis have to cope with persistent arthralgia presenting at a young age. Painful joints may require treatment with salicylates or nonsteroidal anti-inflammatory drugs (NSAIDS) [<a class="bk_pop" href="#jh.REF.vaiopoulos.2003.227">Vaiopoulos et al 2003</a>].</div></li><li class="half_rhythm"><div>Severe cardiac failure is treated with ACE inhibitors, diuretics, cardiac glycosides, and possibly deferoxamine. If left untreated, cardiac disease progresses rapidly and becomes refractory to treatment, leading to death in most cases. Orthotopic heart transplantation has been used on occasion [<a class="bk_pop" href="#jh.REF.caines.2005.486">Caines et al 2005</a>].</div></li><li class="half_rhythm"><div>Liver steatosis and fibrosis are treated with appropriately early phlebotomy [<a class="bk_pop" href="#jh.REF.camaschella.2002.242">Camaschella et al 2002</a>]; however, it is uncertain whether these features are reversible. Reversibility of liver fibrosis has been reported in individuals treated for <i>HFE</i>-associated hemochromatosis [<a class="bk_pop" href="#jh.REF.falize.2006.472">Falize et al 2006</a>].</div></li><li class="half_rhythm"><div>Cirrhosis is thought to be irreversible despite iron removal. Individuals with cirrhosis should undergo endoscopic evaluation to document the presence of varices and should be treated with propranolol or nadolol, as indicated. In advanced disease, orthotopic liver transplantation (OLT) could be considered. Of note, individuals with hereditary hemochromatosis undergoing OLT display an overall lower survival than individuals undergoing OLTs for other causes of liver disease. Because most post-transplantation deaths occur in the perioperative period from cardiac disease or infection, it is advisable to remove as much of excess iron stores as possible before OLT even though the effect of excess tissue iron on survival post-OLT is not known [Tavill 2001].</div></li><li class="half_rhythm"><div>Diabetes mellitus may require insulin administration; successful iron removal may improve its course [<a class="bk_pop" href="#jh.REF.angelopoulos.2007.192">Angelopoulos et al 2007</a>].</div></li></ul></div><div id="jh.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Individuals with biochemical evidence of iron overload but without evidence of organ dysfunction or failure should be encouraged to undergo regular phlebotomies until excess iron stores are depleted to prevent the development of complications associated with excess iron stores.</p><p>Treatment by phlebotomy in presymptomatic stages can prevent organ damage.</p></div><div id="jh.Prevention_of_Secondary_Complications"><h3>Prevention of Secondary Complications</h3><p>HRT prevents the development of osteoporosis.</p></div><div id="jh.Surveillance"><h3>Surveillance</h3><p>Whenever hepatic cirrhosis is identified, monitoring for hepatocellular cancer is recommended. Most hepatologists propose twice-yearly screening with abdominal ultrasound examination and serum alpha-fetoprotein concentration [Tavill 2001].</p></div><div id="jh.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Alcohol consumption, which has a synergistic effect with iron-induced liver damage in individuals with liver damage</div></li><li class="half_rhythm"><div>Iron-containing preparations and supplemental vitamin C</div></li><li class="half_rhythm"><div>Handling or eating uncooked shellfish or marine fish, because of susceptibility to fatal septicemia from the marine bacterium <i>V vulnificus</i></div></li></ul></div><div id="jh.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Once a diagnosis of JHH has been made in a family, all at-risk family members (i.e., sibs) should be tested for the pathogenic variants identified in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. Family members with two <i>HJV</i> or <i>HAMP</i> pathogenic variants should be followed from early childhood with annual measurement of serum ferritin concentration and transferrin iron saturation to monitor for the development of iron overload.</p><p>If a molecular diagnosis was not made or the genetic status of the sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is unknown, the sibs should be followed from early childhood with annual measurement of serum ferritin concentration and transferrin iron saturation to monitor for the development of iron overload.</p><p>If juvenile hemochromatosis is detected before evidence of organ damage, either by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in relatives at-risk or by biochemical testing (i.e., serum ferritin concentration and transferrin-iron saturation), treatment via phlebotomy can reverse or prevent many of the secondary complications resulting from organ damage.</p><p>See <a href="#jh.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="jh.Pregnancy_Management"><h3>Pregnancy Management</h3><p>All pregnant women with JHH should be under the care of a maternal-fetal medicine specialist, an endocrinologist, and a cardiologist. Preferably women with JHH should be seen by these specialists prior to becoming pregnant.</p><p>Pregnancy in women with untreated JHH is high risk because the increased hemodynamic burden of pregnancy can precipitate cardiac failure in women with an underlying cardiomyopathy. Of note, it is critically important for specialists in endocrinology and infertility to be aware of JHH as a cause of infertility and to evaluate patients for iron overload prior to correcting the underlying hormonal imbalance. In a case report, a young woman who became pregnant following correction of her hypogonadotropic hypogonadism developed fatal cardiogenic shock; she was only identified as having JHH with severe iron overload at the time of presentation of her heart disease [<a class="bk_pop" href="#jh.REF.filali.2004.120">Filali et al 2004</a>].</p></div><div id="jh.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="jh.Genetic_Counseling"><h2 id="_jh_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="jh.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Juvenile hemochromatosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="jh.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes and therefore carry one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with juvenile hemochromatosis are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p><p><b>Carrier (Heterozygote) Detection</b></p><p>Carrier testing of at-risk family members using molecular genetic techniques is possible if both pathogenic variants have been identified in the family.</p></div><div id="jh.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#jh.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Use of samples that have been banked should be explicitly approved in a written, revocable consent by each person from whom the sample is obtained. Such consents should detail all known potential biologic, ethical, social, and legal risks and their implications.</p></div><div id="jh.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for juvenile hemochromatosis are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="jh.Resources"><h2 id="_jh_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Hemochromatosis Society, Inc.</b></div><div>P.O. Box 950871</div><div>Lake Mary FL 32795-0871</div><div><b>Phone:</b> 407-829-4488; 888-655-IRON (4766)</div><div><b>Fax:</b> 407-333-1284</div><div><b>Email:</b> mail@americanhs.org</div><div><a href="http://www.americanhs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.americanhs.org</a></div></li><li class="half_rhythm"><div><b>EFAPH: European Federation of Associations of Patients with Haemochromatosis</b></div><div>4 rue Paul Demange</div><div>Croissy-sur-Seine F-78290</div><div>France</div><div><b>Phone:</b> 00 33 (0)6 08 25 94 04</div><div><b>Email:</b> fcourtois.dom@wanadoo.fr; efaph@gmx.eu</div><div><a href="http://efaph.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.efaph.eu</a></div></li><li class="half_rhythm"><div><b>Haemochromatosis Society</b></div><div>Haemochromatosis UK Office</div><div>Henrith Business Centre, 3 Enterprise Way</div><div>Pinchbeck, Spalding Lincolnshire PE11 3YR</div><div>United Kingdom</div><div><b>Phone:</b> 03030 401 101; 03030 401 102</div><div><b>Email:</b> office@huk.org.uk; helpline@huk.org.uk</div><div><a href="http://haemochromatosis.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.haemochromatosis.org.uk</a></div></li><li class="half_rhythm"><div><b>Canadian Hemochromatosis Society</b></div><div>7000 Minoru Boulevard</div><div>Suite 285</div><div>Richmond British Columbia V6Y 3Z5</div><div>Canada</div><div><b>Phone:</b> 877-BAD-IRON (1-877-223-4766); 604-279-7135</div><div><b>Fax:</b> 604-279-7138</div><div><b>Email:</b> office@toomuchiron.ca</div><div><a href="http://www.toomuchiron.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.toomuchiron.ca</a></div></li><li class="half_rhythm"><div><b>Iron Disorders Institute (IDI)</b></div><div><b>Phone:</b> 888-565-4766 (Toll-free Information Request Line); 864-292-1175</div><div><b>Email:</b> info@irondisorders.org</div><div><a href="http://www.irondisorders.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.irondisorders.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/hereditary-hemochromatosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemochromatosis</a></div></li></ul></div><div id="jh.Molecular_Genetics"><h2 id="_jh_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="jh.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Juvenile Hereditary Hemochromatosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1170/table/jh.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__jh.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_jh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_jh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_jh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_jh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_jh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_jh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_jh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/57817" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HAMP</i></a></td><td headers="hd_b_jh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=57817" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P81172" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hepcidin</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/HAMP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HAMP @ LOVD</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HAMP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HAMP</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HAMP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HAMP</a></td></tr><tr><td headers="hd_b_jh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/148738" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HJV</i></a></td><td headers="hd_b_jh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=148738" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q6ZVN8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemojuvelin</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/HFE2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HFE2 @ LOVD</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HJV" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HJV</a></td><td headers="hd_b_jh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HJV[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HJV</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="jh.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="jh.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Juvenile Hereditary Hemochromatosis (<a href="/omim/602390,606464,608374,613313" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1170/table/jh.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__jh.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602390" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602390</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOCHROMATOSIS, TYPE 2A; HFE2A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606464" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606464</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEPCIDIN ANTIMICROBIAL PEPTIDE; HAMP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608374" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608374</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOJUVELIN; HJV</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613313" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613313</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOCHROMATOSIS, TYPE 2B; HFE2B</td></tr></tbody></table></div></div><p><b><i>HJV</i> (<i>HFE2</i>)</b></p><p><b>Gene structure.</b>
<i>HJV</i> comprises four exons. The first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> is not translated. Multiple alternate <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> has been observed with five potential transcripts defined. The <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is 2.2 kb in size and is highly expressed in liver, skeletal, and cardiac muscle. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1170/#jh.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 30 different <i>HJV</i> pathogenic variants, all in the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>, have been identified so far in either <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> form. The majority of pathogenic variants appear to be <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a>; however, the <i>HJV</i> variant p.Gly320Val is the most prevalent <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> reported to date, representing more than 50% of all detected pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals worldwide.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The full-length hemojuvelin protein comprising 426 amino acids is predicted to be approximately 41 kd in size. Bioinformatic analyses revealed that a 35-amino-acid hydrophobic signal peptide is at the N-terminal. At the C-terminal, a transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and a glycophosphatidyl inositol (GPI) addition signal sequence exist. The GPI anchor is functional in vitro [<a class="bk_pop" href="#jh.REF.zhang.2005.33885">Zhang et al 2005</a>]. At position 98, a tri-amino-acid RGD (Arg-Gly-Asp) domain is thought to be important in cell adhesion. A partial vWF-like domain spans the central portion of the protein (aa 167-253). Several cleavage sites are predicted in hemojuvelin including furin and repulsive guidance molecule (RGM) autocatalytic sites. Overall, the hemojuvelin protein is about 91% homologous to RGM type C in mouse.</p><p>Two <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> of hemojuvelin have been identified: the full-length protein and the disulphide bonded N- and C-terminal chains of hemojuvelin cleaved at the Asp-Pro RGM autocatalytic cleavage site. A soluble form of hemojuvelin is released or secreted and competes with the membrane-bound form of hemojuvelin [<a class="bk_pop" href="#jh.REF.lin.2005.2884">Lin et al 2005</a>]. Iron modulates the release of soluble hemojuvelin [<a class="bk_pop" href="#jh.REF.lin.2005.2884">Lin et al 2005</a>, <a class="bk_pop" href="#jh.REF.silvestri.2007.4503">Silvestri et al 2007</a>, <a class="bk_pop" href="#jh.REF.zhang.2007.12547">Zhang et al 2007</a>], and in primary hepatocytes increasing amounts of soluble hemojuvelin reduced hepcidin <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> expression [<a class="bk_pop" href="#jh.REF.lin.2005.2884">Lin et al 2005</a>].</p><p>Hemojuvelin is a key upstream regulator of hepcidin expression. Hemojuvelin acts as a coreceptor for bone morphogenetic protein (BMP) signaling in the hepatocyte [<a class="bk_pop" href="#jh.REF.babitt.2006.531">Babitt et al 2006</a>], signaling via BMP receptors and SMADs. Binding of BMPs to their receptor results in the phosphorylation of downstream receptor SMADs including SMAD 1, 5, and 8. In turn these bind to SMAD4, the terminal transcriptional effector critical for mediating hemojuvelin/BMP induction of hepcidin [<a class="bk_pop" href="#jh.REF.wang.2005.399">Wang et al 2005</a>]. Recently, BMP6 has been shown to be the critical regulator of hepcidin signaling through the BMP receptors [<a class="bk_pop" href="#jh.REF.andriopoulos.2009.482">Andriopoulos et al 2009</a>, <a class="bk_pop" href="#jh.REF.meynard.2009.478">Meynard et al 2009</a>].</p><p>Membrane-bound hemojuvelin is regulated by the serine protease matriptase-2, with hemojuvelin being a key substrate for the proteolytic activity of matriptase-2. Pathogenic variants in <i>TMPRSS6</i>, encoding matriptase-2, underlie iron-refractory iron deficiency anemia (IRIDA), an inherited severe iron deficiency anemia caused by excess hepcidin levels [<a class="bk_pop" href="#jh.REF.finberg.2008.569">Finberg et al 2008</a>]. People with IRIDA have inappropriately elevated levels of the iron regulatory hormone hepcidin, because of a failure of matriptase&#x02011;2 to cleave hemojuvelin resulting in unregulated stimulation of hepcidin expression despite low iron levels [<a class="bk_pop" href="#jh.REF.lee.2009.87">Lee 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Individuals with pathogenic variants in hemojuvelin have extremely low levels of hepcidin in urine, suggesting that hemojuvelin normally regulates hepcidin expression [<a class="bk_pop" href="#jh.REF.papanikolaou.2004.77">Papanikolaou et al 2004</a>]. Similarly, hepcidin levels are depressed in hemojuvelin knockout mice [<a class="bk_pop" href="#jh.REF.huang.2005.2187">Huang et al 2005</a>, <a class="bk_pop" href="#jh.REF.niederkofler.2005.2180">Niederkofler et al 2005</a>]. Furthermore, siRNA knockdown of hemojuvelin resulted in decreased hepcidin <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> expression in primary hepatocytes, underscoring hemojuvelin&#x02019;s critical role in modulating hepcidin. Loss of hemojuvelin function results in decreased BMP signaling in the liver, with associated decreased hepcidin expression.</p><p><b><i>HAMP</i> (<i>HEPC</i>)</b></p><p><b>Gene structure.</b>
<i>HAMP</i> comprises three exons. Exon 3 encodes the active 25-amino-acid peptide. The hepcidin <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is 0.4 kb in size. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1170/#jh.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Six different pathogenic variants in <i>HAMP</i> causing juvenile hemochromatosis in six independent families have been reported to date [<a class="bk_pop" href="#jh.REF.roetto.2003.21">Roetto et al 2003</a>, <a class="bk_pop" href="#jh.REF.delatycki.2004.378">Delatycki et al 2004</a>, <a class="bk_pop" href="#jh.REF.matthes.2004.2181">Matthes et al 2004</a>, <a class="bk_pop" href="#jh.REF.roetto.2004.2407">Roetto et al 2004</a>, <a class="bk_pop" href="#jh.REF.rideau.2007.127">Rideau et al 2007</a>]. Pathogenic variants have been reported in both coding and non-coding regions of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The 84-amino-acid pre-protein contains an N-terminal signal sequence (24 amino acid) and a penta arginyl proteolysis site, which is used to produce the active C-terminal 25-amino-acid peptide. The active peptide comprises eight cysteines forming four disulfide bridges. As hepcidin is a small peptide, it is filtered by the kidney and detectable in the urine. Hepcidin is predominantly expressed in liver, and detected in much lower amounts in heart, brain, lung, and other tissues. Hepcidin functions as a key liver-produced hormone regulating intestinal iron absorption and macrophage iron release. Hepcidin interacts with ferroportin to mediate ferroportin internalization and subsequent degradation. When iron overload occurs, hepcidin is secreted and serves to limit plasma iron concentration by preventing iron uptake in the intestine and preventing iron release from macrophages. In contrast, in the clinical setting of iron deficiency, hepcidin is suppressed to allow intestinal iron absorption.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Individuals with mutated hepcidin fail to prevent iron uptake in the intestine, resulting in iron overload. Macrophages are iron-depleted as a result of failure of hepcidin action.</p></div><div id="jh.References"><h2 id="_jh_References_">References</h2><div id="jh.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="jh.REF.aguilarmartinez.1996.1895">Aguilar-Martinez P, Biron C, Masmejean C, Jeanjean P, Schved JF. A novel mutation in the iron responsive element of ferritin L-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">88</span>:1895.</span> [<a href="/pubmed/8781450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8781450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.andriopoulos.2009.482">Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, Knutson MD, Pietrangelo A, Vukicevic S, Lin HY, Babitt JL. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:482–7.</span> [<a href="/pmc/articles/PMC2810136/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2810136</span></a>] [<a href="/pubmed/19252486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19252486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.angelopoulos.2007.192">Angelopoulos N, Papanikolaou G, Noutsou M, Rombopoulos G, Goula A, Tolis G. Glucose metabolism, insulin secretion and insulin sensitivity in juvenile hemochromatosis. A case report and review of the literature. <span><span class="ref-journal">Exp Clin Endocrinol Diabetes. </span>2007;<span class="ref-vol">115</span>:192–7.</span> [<a href="/pubmed/17427110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17427110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.angelopoulos.2005.1744">Angelopoulos NG, Goula A, Dimitriou E, Tolis G. Reversibility of hypogonadotropic hypogonadism in a patient with the juvenile form of hemochromatosis. <span><span class="ref-journal">Fertil Steril. </span>2005;<span class="ref-vol">84</span>:1744.</span> [<a href="/pubmed/16359978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16359978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.angelopoulos.2006.150">Angelopoulos NG, Goula AK, Papanikolaou G, Tolis G. Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. <span><span class="ref-journal">Osteoporos Int. </span>2006;<span class="ref-vol">17</span>:150–5.</span> [<a href="/pubmed/15997423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15997423</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.babitt.2006.531">Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:531–9.</span> [<a href="/pubmed/16604073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16604073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.beutler.2003.305">Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, Waalen J, Vulpe C. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2003;<span class="ref-vol">31</span>:305–9.</span> [<a href="/pubmed/14636643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14636643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.brakensiek.2009.493">Brakensiek K, Fegbeutel C, M&#x000e4;lzer M, Str&#x000fc;ber M, Kreipe H, Stuhrmann M. Juvenile hemochromatosis due to homozygosity for the G320V mutation in the HJV gene with fatal outcome. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">76</span>:493–5.</span> [<a href="/pubmed/19796184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19796184</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.caines.2005.486">Caines AE, Kpodonu J, Massad MG, Chaer R, Evans A, Lee JC, Geha AS. Cardiac transplantation in patients with iron overload cardiomyopathy. <span><span class="ref-journal">J Heart Lung Transplant. </span>2005;<span class="ref-vol">24</span>:486–8.</span> [<a href="/pubmed/15797753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15797753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.camaschella.1998.227">Camaschella C. Juvenile haemochromatosis. <span><span class="ref-journal">Baillieres Clin Gastroenterol. </span>1998;<span class="ref-vol">12</span>:227–35.</span> [<a href="/pubmed/9890070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9890070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.camaschella.2000.14">Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">25</span>:14–5.</span> [<a href="/pubmed/10802645" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10802645</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.camaschella.2002.242">Camaschella C, Roetto A, De Gobbi M. Juvenile hemochromatosis. <span><span class="ref-journal">Semin Hematol. </span>2002;<span class="ref-vol">39</span>:242–8.</span> [<a href="/pubmed/12382199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12382199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.de_domenico.2006.92">De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due to mutations in ferroportin. <span><span class="ref-journal">Haematologica. </span>2006;<span class="ref-vol">91</span>:92–5.</span> [<a href="/pmc/articles/PMC3718253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3718253</span></a>] [<a href="/pubmed/16434376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16434376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.de_gobbi.2000.865">De Gobbi M, Pasquero P, Brunello F, Paccotti P, Mazza U, Camaschella C. Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. <span><span class="ref-journal">Haematologica. </span>2000;<span class="ref-vol">85</span>:865–7.</span> [<a href="/pubmed/10942934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10942934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.de_gobbi.2002.973">De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, Politou M, Lockitch G, Girelli D, Fargion S, Cox TM, Gasparini P, Cazzola M, Camaschella C. Natural history of juvenile haemochromatosis. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:973–9.</span> [<a href="/pubmed/12060140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12060140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.delatycki.2004.378">Delatycki MB, Allen KJ, Gow P, MacFarlane J, Radomski C, Thompson J, Hayden MR, Goldberg YP, Samuels ME. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">65</span>:378–83.</span> [<a href="/pubmed/15099344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15099344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.fabio.2007.362">Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:362–4.</span> [<a href="/pubmed/16960153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16960153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.falize.2006.472">Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. <span><span class="ref-journal">Hepatology. </span>2006;<span class="ref-vol">44</span>:472–7.</span> [<a href="/pubmed/16871557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16871557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.filali.2004.120">Filali M, Le Jeunne C, Durand E, Grinda JM, Roetto A, Daraio F, Bruneval P, Jeunemaitre X, Gimenez-Roqueplo AP. Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2004;<span class="ref-vol">33</span>:120–4.</span> [<a href="/pubmed/15315789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15315789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.finberg.2008.569">Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). <span><span class="ref-journal">Nat Genet. </span>2008;<span class="ref-vol">40</span>:569–71.</span> [<a href="/pmc/articles/PMC3104019/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3104019</span></a>] [<a href="/pubmed/18408718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18408718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.fung.2004.5">Fung EB, Fischer R, Pakbaz Z, Fagaly RL, Vichinsky E, Starr TN, Ewing T, Paulson DN, Hassenzahl WV, Harmatz P. The new SQUID biosusceptometer at Oakland: first year of experience. <span><span class="ref-journal">Neurol Clin Neurophysiol. </span>2004;<span class="ref-vol">2004</span>:5.</span> [<a href="/pubmed/16012600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16012600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.gandon.2004.357">Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">363</span>:357–62.</span> [<a href="/pubmed/15070565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15070565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.gehrke.2005.425">Gehrke SG, Pietrangelo A, Kasc&#x000e1;k M, Braner A, Eisold M, Kulaksiz H, Herrmann T, Hebling U, Bents K, Gugler R, Stremmel W. HJV gene mutations in European patients with juvenile hemochromatosis. <span><span class="ref-journal">Clin Genet. </span>2005;<span class="ref-vol">67</span>:425–8.</span> [<a href="/pubmed/15811010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15811010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.girelli.1995.4050">Girelli D, Corrocher R, Bisceglia L, Olivieri O, De Franceschi L, Zelante L, Gasparini P. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the "Verona mutation"). <span><span class="ref-journal">Blood. </span>1995;<span class="ref-vol">86</span>:4050–3.</span> [<a href="/pubmed/7492760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7492760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.gordeuk.2003.299">Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, Onyekwere O, Kittles R, Pignatti E, Montosi G, Garuti C, Gangaidzo IT, Gomo ZA, Moyo VM, Rouault TA, MacPhail P, Pietrangelo A. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2003;<span class="ref-vol">31</span>:299–304.</span> [<a href="/pubmed/14636642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14636642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.huang.2005.2187">Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. <span><span class="ref-journal">J Clin Invest. </span>2005;<span class="ref-vol">115</span>:2187–91.</span> [<a href="/pmc/articles/PMC1180543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180543</span></a>] [<a href="/pubmed/16075059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16075059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.kelly.1998.607">Kelly AL, Rhodes DA, Roland JM, Schofield P, Cox TM. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. <span><span class="ref-journal">QJM. </span>1998;<span class="ref-vol">91</span>:607–18.</span> [<a href="/pubmed/10024915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10024915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.koyama.2005.740">Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, Goto H, Kidokoro R. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. <span><span class="ref-journal">J Hepatol. </span>2005;<span class="ref-vol">43</span>:740–2.</span> [<a href="/pubmed/16099526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16099526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.lanzara.2004.4317">Lanzara C, Roetto A, Daraio F, Rivard S, Ficarella R, Simard H, Cox TM, Cazzola M, Piperno A, Gimenez-Roqueplo AP, Grammatico P, Volinia S, Gasparini P, Camaschella C. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:4317–21.</span> [<a href="/pubmed/14982873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14982873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.le_gac.2004.674">Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. <span><span class="ref-journal">Br J Haematol. </span>2004;<span class="ref-vol">125</span>:674–8.</span> [<a href="/pubmed/15147384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15147384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.lee.2009.87">Lee P. Role of matriptase-2 (TMPRSS6) in iron metabolism. <span><span class="ref-journal">Acta Haematol. </span>2009;<span class="ref-vol">122</span>:87–96.</span> [<a href="/pmc/articles/PMC2855275/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2855275</span></a>] [<a href="/pubmed/19907145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19907145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.lee.2004a.4669">Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. <span><span class="ref-journal">Blood. </span>2004a;<span class="ref-vol">103</span>:4669–71.</span> [<a href="/pubmed/14982867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14982867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.lee.2002.471">Lee P, Gelbart T, West C, Halloran C, Beutler E. Seeking candidate mutations that affect iron homeostasis. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2002;<span class="ref-vol">29</span>:471–87.</span> [<a href="/pubmed/12547238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12547238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.lee.2004b.224">Lee PL, Barton JC, Brandhagen D, Beutler E. Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. <span><span class="ref-journal">Br J Haematol. </span>2004b;<span class="ref-vol">127</span>:224–9.</span> [<a href="/pubmed/15461631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15461631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.lin.2005.2884">Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:2884–9.</span> [<a href="/pubmed/15998830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15998830</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.majore.2004.400">Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P. HAMP gene mutation c.208T&#x0003e;C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:400.</span> [<a href="/pubmed/15024747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15024747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.matthes.2004.2181">Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, Darbellay R, Rubbia-Brandt L, Giostra E, Michel M, Ganz T, Beris P. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'UTR of the hepcidin gene. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>:2181–3.</span> [<a href="/pubmed/15198949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15198949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.merryweatherclarke.2003.2241">Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, McHugh PJ, Chapman RW, Pointon JJ, Wimhurst VL, Livesey KJ, Tanphaichitr V, Rochette J, Robson KJ. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:2241–7.</span> [<a href="/pubmed/12915468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12915468</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.meynard.2009.478">Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:478–81.</span> [<a href="/pubmed/19252488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19252488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.montosi.2001.619">Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. <span><span class="ref-journal">J Clin Invest. </span>2001;<span class="ref-vol">108</span>:619–23.</span> [<a href="/pmc/articles/PMC209405/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC209405</span></a>] [<a href="/pubmed/11518736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11518736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.morrison.2003.627">Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. <span><span class="ref-journal">Ann Intern Med. </span>2003;<span class="ref-vol">138</span>:627–33.</span> [<a href="/pubmed/12693884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12693884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.niederkofler.2005.2180">Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. <span><span class="ref-journal">J Clin Invest. </span>2005;<span class="ref-vol">115</span>:2180–6.</span> [<a href="/pmc/articles/PMC1180556/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180556</span></a>] [<a href="/pubmed/16075058" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16075058</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.njajou.2001.213">Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, Snijders PJ, Rutten WP, Sandkuijl LA, Oostra BA, van Duijn CM, Heutink P. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">28</span>:213–4.</span> [<a href="/pubmed/11431687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11431687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.papanikolaou.2004.77">Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Davidas O, Christakis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:77–82.</span> [<a href="/pubmed/14647275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14647275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.pietrangelo.2004.2383">Pietrangelo A. Hereditary hemochromatosis--a new look at an old disease. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>:2383–97.</span> [<a href="/pubmed/15175440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15175440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.pietrangelo.2005.470">Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, Stremmel W, Andreone P, Garuti C. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. <span><span class="ref-journal">Gastroenterology. </span>2005;<span class="ref-vol">128</span>:470–9.</span> [<a href="/pubmed/15685557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15685557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.rideau.2007.127">Rideau A, Mangeat B, Matthes T, Trono D, Beris P. Molecular mechanism of hepcidin deficiency in a patient with juvenile hemochromatosis. <span><span class="ref-journal">Haematologica. </span>2007;<span class="ref-vol">92</span>:127–8.</span> [<a href="/pubmed/17229647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17229647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.roetto.2004.2407">Roetto A, Daraio F, Porporato P, Caruso R, Cox TM, Cazzola M, Gasparini P, Piperno A, Camaschella C. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:2407–9.</span> [<a href="/pubmed/14630809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14630809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.rand.2009.566">Rand EB, Karpen SJ, Kelly S, Mack CL, Malatack JJ, Sokol RJ, Whitington PF. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. <span><span class="ref-journal">J Pediatr. </span>2009;<span class="ref-vol">155</span>:566–71.</span> [<a href="/pubmed/19560784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19560784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.roetto.2003.21">Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">33</span>:21–2.</span> [<a href="/pubmed/12469120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12469120</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.silvestri.2007.4503">Silvestri L, Pagani A, Fazi C, Gerardi G, Levi S, Arosio P, Camaschella C. Defective targeting of hemojuvelin to plasma membrane is a common pathogenetic mechanism in juvenile hemochromatosis. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:4503–10.</span> [<a href="/pubmed/17264300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17264300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.tavill.2001.1321">Tavill AS., American Association for the Study of Liver Diseases.  American College of Gastroenterology; American Gastroenterological Association. Diagnosis and management of hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2001;<span class="ref-vol">33</span>:1321–8.</span> [<a href="/pubmed/11343262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11343262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.vaiopoulos.2003.227">Vaiopoulos G, Papanikolaou G, Politou M, Jibreel I, Sakellaropoulos N, Loukopoulos D. Arthropathy in juvenile hemochromatosis. <span><span class="ref-journal">Arthritis Rheum. </span>2003;<span class="ref-vol">48</span>:227–30.</span> [<a href="/pubmed/12528123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12528123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.varkonyi.2000.252">Varkonyi J, Kaltwasser JP, Seidl C, Kollai G, Andrikovics H, Tordai A. A case of non-HFE juvenile haemochromatosis presenting with adrenocortical insufficiency. <span><span class="ref-journal">Br J Haematol. </span>2000;<span class="ref-vol">109</span>:252–3.</span> [<a href="/pubmed/10896410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10896410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.wang.2005.399">Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, Cooperman S, Eckhaus M, Rouault T, Mishra L, Deng CX. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. <span><span class="ref-journal">Cell Metab. </span>2005;<span class="ref-vol">2</span>:399–409.</span> [<a href="/pubmed/16330325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16330325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.zhang.2007.12547">Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. <span><span class="ref-journal">J Biol Chem. </span>2007;<span class="ref-vol">282</span>:12547–56.</span> [<a href="/pubmed/17331953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17331953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.zhang.2005.33885">Zhang AS, West AP Jr, Wyman AE, Bjorkman PJ, Enns CA. Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells. <span><span class="ref-journal">J Biol Chem. </span>2005;<span class="ref-vol">280</span>:33885–94.</span> [<a href="/pubmed/16103117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16103117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.whitington.2008.e1615">Whitington PF, Kelly S. Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin. <span><span class="ref-journal">Pediatrics. </span>2008;<span class="ref-vol">121</span>:e1615–21.</span> [<a href="/pubmed/18474533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18474533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.whitington.2005.544">Whitington PF, Malladi P. Neonatal hemochromatosis: is it an alloimmune disease? <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2005;<span class="ref-vol">40</span>:544–9.</span> [<a href="/pubmed/15861012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15861012</span></a>]</div></li></ul></div><div id="jh.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="jh.REF.brissot.2006.36">Brissot P, de Bels F. Current approaches to the management of hemochromatosis. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2006:36–41.</span> [<a href="/pubmed/17124037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17124037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.franchini.2006.202">Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. <span><span class="ref-journal">Am J Hematol. </span>2006;<span class="ref-vol">81</span>:202–9.</span> [<a href="/pubmed/16493621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16493621</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.gasparini.2004.341">Gasparini P, Camaschella C. Hereditary hemochromatosis: is the gene race over? <span><span class="ref-journal">Eur J Hum Genet. </span>2004;<span class="ref-vol">12</span>:341–2.</span> [<a href="/pubmed/15094740" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15094740</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.nelson.2005.71">Nelson JE, Kowdley KV. Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management. <span><span class="ref-journal">Curr Gastroenterol Rep. </span>2005;<span class="ref-vol">7</span>:71–80.</span> [<a href="/pubmed/15701302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15701302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.papanikolaou.2001.744">Papanikolaou G, Politou M, Roetto A, Bosio S, Sakelaropoulos N, Camaschella C, Loukopoulos D. Linkage to chromosome 1q in Greek families with juvenile hemochromatosis. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2001;<span class="ref-vol">27</span>:744–9.</span> [<a href="/pubmed/11778658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11778658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.pissia.2004.742">Pissia M, Polonifi K, Politou M, Lilakos K, Sakellaropoulos N, Papanikolaou G. Prevalence of the G320V mutation of the HJV gene, associated with juvenile hemochromatosis, in Greece. <span><span class="ref-journal">Haematologica. </span>2004;<span class="ref-vol">89</span>:742–3.</span> [<a href="/pubmed/15194541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15194541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.rivard.2003.585">Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, Simard R, D'Adamo AP, F&#x000e9;rec C, Camaschella C, Mura C, Roetto A, De Braekeleer M, Bechner L, Gasparini P. Juvenile hemochromatosis locus maps to chromosome 1q in a French Canadian population. <span><span class="ref-journal">Eur J Hum Genet. </span>2003;<span class="ref-vol">11</span>:585–9.</span> [<a href="/pubmed/12891378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12891378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="jh.REF.roetto.1999.1388">Roetto A, Totaro A, Cazzola M, Cicilano M, Bosio S, D'Ascola G, Carella M, Zelante L, Kelly AL, Cox TM, Gasparini P, Camaschella C. Juvenile hemochromatosis locus maps to chromosome 1q. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:1388–93.</span> [<a href="/pmc/articles/PMC1377875/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377875</span></a>] [<a href="/pubmed/10205270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10205270</span></a>]</div></li></ul></div></div><div id="jh.Chapter_Notes"><h2 id="_jh_Chapter_Notes_">Chapter Notes</h2><div id="jh.Author_Notes"><h3>Author Notes</h3><p>Web: <a href="http://www.xenon-pharma.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><u>www.xenon-pharma.com</u></a></p></div><div id="jh.Author_History"><h3>Author History</h3><p>Y Paul Goldberg, MB ChB, PhD, FRCPC (2005-present)<br />Julie MacFarlane, MS, CCGC; Xenon Pharmaceuticals Inc (2005-2011)<br />George Papanikalaou, MD, PhD; National and Kapodistrian University of Athens (2005-2011)</p></div><div id="jh.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>11 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 February 2005 (me) Review posted to live Web site</div></li><li class="half_rhythm"><div>12 July 2004 (pg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1170</span><span class="label">PMID: <a href="/pubmed/20301349" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301349</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ebj/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/jps/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1170&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1170/?report=reader">PubReader</a></li><li><a href="/books/NBK1170/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1170" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1170" style="display:none" title="Cite this Page"><div class="bk_tt">Goldberg YP. Juvenile Hereditary Hemochromatosis. 2005 Feb 17 [Updated 2011 Aug 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1170/pdf/Bookshelf_NBK1170.pdf">PDF version of this page</a> (488K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#jh.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#jh.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#jh.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#jh.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#jh.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#jh.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#jh.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#jh.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#jh.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#jh.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#jh.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=148738[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HJV</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=57817[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HAMP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1499216" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1499216" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1499216" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1499216" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301613" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">HFE</i> Hemochromatosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">HFE</i> Hemochromatosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Barton JC, Edwards CQ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301523" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TFR2</i>-Related Hereditary Hemochromatosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TFR2</i>-Related Hereditary Hemochromatosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">De Gobbi M, Roetto A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301599" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23418762" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary hemochromatosis.</a><span class="source">[Am Fam Physician. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary hemochromatosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Crownover BK, Covey CJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am Fam Physician. 2013 Feb 1; 87(3):183-90. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24624460" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kalfa TA, Connor JA, Begtrup AH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301349" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301349" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419f3dde089116958c3e9">Juvenile Hereditary Hemochromatosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Juvenile Hereditary Hemochromatosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:24:51-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D65BEE0403EC1000000000979036A&amp;ncbi_session=CE8D65BEE0419F31_2425SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1170%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1170&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1170/&amp;ncbi_pagename=Juvenile Hereditary Hemochromatosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D65BEE0419F31_2425SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>